Home > Press > Copernicus to Receive Increased Support from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic F
Copernicus Therapeutics, Inc., announced today it will receive up to $5.2 million from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) to support continued development of a potential gene therapy for cystic fibrosis. This continued funding is a result of satisfactory progress shown in 2006 and represents a significant increase in funding over that received in 2006.
Copernicus to Receive Increased Support from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic F
Cleveland, OH | Posted on February 15th, 2007
Copernicus' unique, non-viral nanoparticle formulation is intended to deliver a normal copy of the CF gene to the affected lung cells of CF patients, and may provide a therapy that treats the root cause of CF. Copernicus' first clinical trial, supported by CFFT, demonstrated the desired safety profile and encouraging biological changes were observed.
Cystic fibrosis is the most common fatal genetic disease in the United States, affecting approximately 30,000 children and adults. It causes serious lung infections and digestive complications. About 10 million Americans are unknowing carriers of a CF gene.
"We have had a productive relationship for a number of years with CFFT and we share the common goal of providing a safe and effective therapeutic for people with CF," said Robert C. Moen, M.D., Ph.D., president and CEO of Copernicus. "Our relationship with CFFT involves not only financial support, but also support at the scientific level through a research review committee comprised of outstanding academic scientists active in the areas required for development of a successful product. We look forward to working with CFFT in meeting the critical need for an effective gene-based therapy for the lung manifestations of CF."
"We are encouraged by the promise of Copernicus' technology and the scientific rigor the firm is applying to the development process," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation and CFFT. "Gene-based therapies offer hope for potentially lifesaving treatments that tackle the root cause of CF, rather than just the symptoms. We are grateful for the many people that generously support CFF and provide CFFT with critical financial resources to support this kind of research."
About Cystic Fibrosis Foundation, CFFT, and Copernicus
Copernicus Therapeutics, Inc., a privately held biotechnology company, is dedicated to delivering the promise of nucleic acid therapeutics. The same technology that is being tested for its ability to deliver the CF gene to the lung of CF patients can be applied to treating serious lung infections caused by influenza A, bird flu, and other respiratory viruses, as well as for treating a variety of blinding disorders. The Copernicus multi-component delivery platform can be used to develop nucleic acid therapies for numerous human diseases. Additional information about Copernicus is available at http://www.cgsys.com .
The mission of the Cystic Fibrosis Foundation is to assure the development of the means to cure and control CF, and to improve the quality of life for those with the disease. CFFT is the nonprofit drug development affiliate of the CF Foundation that operates drug discovery, development and evaluation efforts. Total support for CFFT is provided by the CF Foundation. The CF Foundation has initiated a special gifts campaign, Milestones to a Cure, with a target goal of $175 million to support programs like the one with Copernicus. For more information about CF, the CF Foundation or CFFT, call (800) FIGHT CF or visit http://www.cff.org .
For more information, please click here
Copernicus Therapeutics, Inc.
Robert C. Moen, M.D., Ph.D., President & CEO,
Copernicus Therapeutics, Inc.
Mark J. Cooper, M.D., Sr. V.P. of Science and
Medical Affairs, 216-231-0227 x23
Cystic Fibrosis Foundation
Laurie Fink, Director of Media Relations,
Copyright © Business Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014
Unraveling the light of fireflies December 17th, 2014
Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014
Instant-start computers possible with new breakthrough December 19th, 2014
Aculon Hires New Business Development Director December 19th, 2014
Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014
Longhorn beetle inspires ink to fight counterfeiting November 5th, 2014
Iran-Made Respiratory Nano Masks Provided to Hajj Pilgrims October 23rd, 2014
Japanese gold leaf artists worked on a nano-scale: Study demonstrates X-ray fluorescence spectroscopy is a non-destructive way to date artwork July 3rd, 2014
Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013
SUNY Poly NanoCollege Faculty Member Selected as American Physical Society Fellow: SUNY Poly Associate Professor of Nanoscience Dr. Vincent LaBella Recognized for Significant Technological Innovations that Enable Interactive Learning December 17th, 2014
“Line dancing bacteria win the 2014 Dolomite and Lab on a Chip Video Competition” December 16th, 2014
Lifeboat Foundation gives 2014 Guardian Award to Elon Musk December 16th, 2014
UCLA engineers first to detect and measure individual DNA molecules using smartphone microscope December 15th, 2014